These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21221517)

  • 41. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.
    Schmand B; Eikelenboom P; van Gool WA;
    J Am Geriatr Soc; 2011 Sep; 59(9):1705-10. PubMed ID: 21883100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration.
    Poljansky S; Ibach B; Hirschberger B; Männer P; Klünemann H; Hajak G; Marienhagen J
    Eur Arch Psychiatry Clin Neurosci; 2011 Sep; 261(6):433-46. PubMed ID: 21207049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease.
    Kimura A; Takemura M; Saito K; Yoshikura N; Hayashi Y; Inuzuka T
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):126-131. PubMed ID: 27330118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MRI-based Alzheimer's disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer's disease.
    Liu W; Au LWC; Abrigo J; Luo Y; Wong A; Lam BYK; Fan X; Kwan PWL; Ma HW; Ng AYT; Chen S; Leung EYL; Ho CL; Wong SHM; Chu WC; Ko H; Lau AYL; Shi L; Mok VCT;
    Aging (Albany NY); 2021 May; 13(10):13496-13514. PubMed ID: 34091443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
    Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
    Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions.
    Ossenkoppele R; van der Flier WM; Verfaillie SC; Vrenken H; Versteeg A; van Schijndel RA; Sikkes SA; Twisk J; Adriaanse SM; Zwan MD; Boellaard R; Windhorst AD; Barkhof F; Scheltens P; Lammertsma AA; van Berckel BN
    Neurology; 2014 May; 82(20):1768-75. PubMed ID: 24748672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Relevance of [
    Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
    Drago V; Babiloni C; Bartrés-Faz D; Caroli A; Bosch B; Hensch T; Didic M; Klafki HW; Pievani M; Jovicich J; Venturi L; Spitzer P; Vecchio F; Schoenknecht P; Wiltfang J; Redolfi A; Forloni G; Blin O; Irving E; Davis C; Hårdemark HG; Frisoni GB
    J Alzheimers Dis; 2011; 26 Suppl 3():159-99. PubMed ID: 21971460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging.
    Chetelat G; Baron JC
    Neuroimage; 2003 Feb; 18(2):525-41. PubMed ID: 12595205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating 2-[
    Gjerum L; Frederiksen KS; Henriksen OM; Law I; Bruun M; Simonsen AH; Mecocci P; Baroni M; Dottorini ME; Koikkalainen J; Lötjönen J; Hasselbalch SG
    Neuroimage Clin; 2020; 27():102267. PubMed ID: 32417727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
    Rabinovici GD; Gatsonis C; Apgar C; Chaudhary K; Gareen I; Hanna L; Hendrix J; Hillner BE; Olson C; Lesman-Segev OH; Romanoff J; Siegel BA; Whitmer RA; Carrillo MC
    JAMA; 2019 Apr; 321(13):1286-1294. PubMed ID: 30938796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status.
    Lange C; Suppa P; Pietrzyk U; Makowski MR; Spies L; Peters O; Buchert R;
    J Alzheimers Dis; 2018; 61(1):373-388. PubMed ID: 29154285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J; Wilson H; Politis M;
    J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.